1Galife N, Humbert M, Vachiery JL, et al. 2015 ESC/ERSGuidelines for the diagnosis and treatment of pulmonaryhypertension: The Joint Task Force for the Diagnosis andTreatment of Pulmonary Hypertension of the European Society ofCardiology ( ESC) and the European Respiratory Society ( ERS):Endorsed by : Association for European Paediatric and CongenitalCardiology ( AEPC ),International Society for Heart and LungTransplantation (ISHLT) [ J]. Eur Heart J, 2016,37 ( 1 ) :67-119. DOI: 10. 1093/eurhearlj/ehv317.
3Guazzi M , Arena R. Pulmonary hypertension with left-sided heartdisease[J]. Nat Rev Cardiol, 2010, 7(11 ) :648-659. DOI: 10.1038/nrcardio, 2010. 144.
4MoGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonaryarterial hypertension: epidemiology and registries[ J]. J Am CollCardiol, 2013, 62(25 Suppl) ;D51-D59. DOI: 10.1016/j. jacc.2013.10.023.
5Simonneau G, Robbins IM, Beghetti M , et al. Updated clinicalclassification of pulmonary hypertension [ J ]. J Am Coll Cardiol,2009,54(1 Suppl) :S43-S54. DOI: 10. 1016/j. jacc. 2009. 04.012.
6Eddahibi S, Adnot S. Anorexigen-induced pulmonaryhypertension and the serotonin (5-HT) hypothesis: lessons for thefuture in pathogenesis[ J]. Respir Res, 2002 , 3(1): 9. DOT :10. 1186/n-181.
7Eddahibi S, Raffestin B, Hamon M, et al. Is the serotonintransporter involved in the pathogenesis of pulmonaryhypertension? [J]. J Lab Clin Med, 2002, 139(4) : 194-201.DOI: 10. 1067/mlc.2002. 122181.
8Eddahibi S, Humbert M, Fadel E, et al. Hyperplasia ofpulmonary artery smooth muscle cells is causally related tooverexpreftftion of the serotonin transporter in primary pulmonaryhypertension[ J]. Chest, 2002,121 (3 Suppl) : 97S-98S. DOI:10. 1378/chest. 121. 3_suppl. 97S.
9Herve P,Launay JM, Scrobohaci ML, et al. Increased plasmaserotonin in primary pulmonary hypertension [ J ]. Am J Med,1995, 99 ? 3 ): 249-254. DOI: 10. 1016/S0002-9343 (99 )80156-9.
